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Background: Persons with a clinically recognizedmyocardial infarction are at increased risk for atrial ﬁbrillation.
However a large proportion of all myocardial infarctions remain clinically unrecognized. Whether subjects with
electrocardiographic signs of an unrecognized myocardial infarction are also at an increased risk of developing
atrial ﬁbrillation is unknown. The objective of this study was to investigate whether unrecognized myocardial
infarction was associated with an increased risk of atrial ﬁbrillation in a prospective population-based cohort
study.
Methods: The study is set within the prospective population-based Rotterdam Study. The study population com-
prised 2505 men and 3670 women without atrial ﬁbrillation at baseline. Participants were classiﬁed based on
electrocardiography, interview, and clinical data into those with recognized myocardial infarction, those with
ECG based unrecognized myocardial infarction and those without myocardial infarction. Atrial ﬁbrillation was
ascertained from ECG assessments as well as medical records.
Results: During a mean follow-up of 11.7 years (SD 5.0), 329 men and 398 women developed atrial ﬁbrillation.
Unrecognized myocardial infarction was associated with a two-fold risk of developing atrial ﬁbrillation in men
(HR: 2.21, 95%CI:1.51 to 3.23) compared to men without a history of myocardial infarction, independent of age,
and cardiovascular risk factors. In women, unrecognized myocardial infarction was not associated with atrial ﬁ-
brillation (HR: 0.92, 95%CI:0.59 to 1.44).
Conclusion: The presence of an unrecognized myocardial infarction is associated with a twofold increased risk of
atrial ﬁbrillation in men, independent of known cardiovascular risk factors.© 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Atrial ﬁbrillation is the most common sustained arrhythmia in the
older population. Its prevalence and incidence increase with age
[1–4]. Atrial ﬁbrillation has signiﬁcant impact on prognosis and qual-
ity of life. It is a major cause of morbidities such as dementia [5],
stroke [6], and heart failure [7] and it is also associated with increased
cardiovascular and overall mortality [8–10]. Persons with a history of
myocardial infarction (MI) are at increased risk of atrial ﬁbrillation
[4,11]. However, it has previously been demonstrated that the overall
detection of MIs is far from complete and that a large proportion of
all MIs remains clinically unrecognized [12,13]. It was previouslyy, Erasmus Medical Center, PO
31 10 7044294; fax: +31 10
er).
Ltd. All rights reserved.estimated that the proportion of unrecognized MIs from all MIs
ranges from 21 to 33% in men and 26 to 54% in women [12–17]. Fur-
thermore, in approximately 1 to 6% of the general elderly population
electrocardiographic characteristics can be detected of an unrecognized
MI [12,14,18]. Whether subjects with electrocardiographic signs of an
unrecognized MI are also at an increased risk of developing atrial ﬁbril-
lation is unknown.
Therefore, the objective of this study was to investigate whether
unrecognized MI was associated with an increased risk of atrial ﬁbril-
lation in a prospective population of community-dwelling elderly.
2. Methods
2.1. Study population
The current study was performed within the Rotterdam Study, a population-based
prospective cohort study, designed to examine the onset of, and risk factors for disease
in older adults, which started with a baseline visit between 1990 and 1993 [19]. All
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were invited to participate (n=10,275). Of them, 7983 (78%) participated in the study. At
baseline, participants were interviewed at home and were examined at the research
center, which included a 10 s, 12-lead resting electrocardiogram (ECG). From that visit
onwards, participants were followed continuously and re-examined at three follow-up
examination rounds (1993–1995, 1997–1999, and 2002–2004). Information on the
presence and occurrence of disease at baseline and during follow-up is available by collab-
oration with the general practitioners in the study area. General practitioners in the
Netherlands have a key position in the Dutch healthcare system. They register all
diagnoses available from their own work and the work from physicians in the hospital
and the out-patient clinic. The medical ethics committee of the Erasmus Medical Center,
Rotterdam, approved the study, and all participants gave informed consent to participate
in the study and to obtain information from treating physicians. The authors of this man-
uscript have certiﬁed that they comply with the Principles of Ethical Publishing in the
International Journal of Cardiology.
2.2. Myocardial infarction assessment
ECGs were processed by the Modular ECG Analysis System (MEANS) to obtain ECG
measurement and interpretation [20–22]. To determine MI, MEANS uses an extensive
set of criteria that is partially derived from the Minnesota code [23]. Subsequently, two
research physicians blinded to other clinical information validated the ECGs selected
by MEANS. A cardiologist, who specialized in ECG methodology, ascertained the ﬁnal
diagnosis of MI. The diagnosis of MI using MEANS is mainly driven by pathological Q
waves and auxiliary criteria, such as QR ratio and R-wave progression. ST-T changes
were not considered as criteria for MI by MEANS, but were taken into account by the
cardiologist validating and ascertaining the diagnosis of MI based on the ECG. Assess-
ment of recognized MI status was done by veriﬁcation of the medical records after
either self-reported MI or ECG abnormalities indicative of prior MI, as reported previ-
ously for the Rotterdam Study [24]. We classiﬁed participants at baseline as follows:
a history of ‘recognized MI’ included people with self-reported MI and/or ECG charac-
teristics matching an MI, conﬁrmed by clinical data. A history of ‘unrecognized MI’
included all participants without documented or self-reported MI, but with ECG char-
acteristics matching an MI. All other participants were classiﬁed as having ‘no MI’.
2.3. Atrial ﬁbrillation assessment
Prevalent and incident atrial ﬁbrillation was ascertained using three methods [1].
At baseline and at each follow-up examination an ECG was recorded, stored digitally,
and analyzed by MEANS [20–22]. Notably, MEANS is characterized by a high sensitivity
(96.6%) and a high speciﬁcity (99.5%) in coding arrhythmias [20]. Additionally, infor-
mation was obtained from the treating general practitioners, which included their
own results as well as results from medical specialists practicing in hospitals and out-
patient clinics. Finally, information was obtained from a nationwide medical registry of
all hospital discharge diagnoses. To verify the diagnosis of atrial ﬁbrillation, all ECGs
with a diagnosis of atrial ﬁbrillation, atrial ﬂutter, or any other rhythm disorder were
coded independently by two research physicians who were blinded to the MEANS di-
agnosis. The judgment of a cardiologist was taken as decisive in those cases in which
disagreement persisted between the coding physicians. We did not distinguish be-
tween atrial ﬁbrillation and atrial ﬂutter when we identiﬁed cases because both condi-
tions are very similar with respect to risk factors and consequences [25,26]. Also, we
did not discriminate between paroxysmal atrial ﬁbrillation and chronic atrial ﬁbrilla-
tion. The date of incident atrial ﬁbrillation was deﬁned as the date of the ﬁrst occur-
rence of symptoms with subsequent ECG veriﬁcation. In a minority of the cases,
when atrial ﬁbrillation had been diagnosed at the research center only and when no
further information was available on a more precise date of onset, we deﬁned the
date of onset as the midpoint of the time interval between examination at which atrial
ﬁbrillation was detected and the previous examination at the research center.
2.4. Vital status
Information on vital status of each participant was obtained on a weekly basis from
the Central Population Register of the municipality of Rotterdam, from collaborating
general practitioners, and by collecting information during follow-up examination
rounds. If no information could be obtained from these sources, the Central Registry
of Genealogy of the Netherlands was consulted. This national institute receives popu-
lation registry records of all inhabitants of the Netherlands who have died.
2.5. Covariable assessment
Age at baseline was included in all analyses. Body mass index (BMI) was calculated
by dividing weight in kilograms by height in squared meters (kg/m2). Blood pressure
was measured twice at the right upper arm with a random zero Hg sphygmomanom-
eter in the sitting position. Systolic and diastolic blood pressures were calculated as
the average of the two consecutive measurements. Serum total cholesterol and
high-density lipoprotein (HDL) cholesterol levels were measured with an automated
enzymatic method. Data on medication use were obtained during the home interview
by copying the labels of all the medication used. Information on smoking status was
also acquired from the home interview. Heart failure was assessed using a validated
score based on the deﬁnition of heart failure by the European Society of Cardiology[27,28]. Prevalent chronic obstructive pulmonary disease (COPD) was obtained from
the medical records, and deﬁned as the diagnosis of COPD by a medical specialist
[29]. Prevalent diabetes mellitus was deﬁned as the use of anti-diabetic medication
or a pre- or post-load serum glucose level of >11.0 mmol/L.
2.6. Population for analysis
The study population comprised 7983 persons. Persons who did not visit the re-
search center at baseline and therefore did not have an ECG recorded were excluded
(n=894). Also those with missing baseline ECG data, due to technical problems or
lack of qualiﬁed personnel, were excluded (n=536). Furthermore 378 participants
with prevalent atrial ﬁbrillation at baseline were excluded from the analyses. This
resulted in a population for analyses of 6175 participants. All participants were
followed from their baseline ECG assessment in the Rotterdam Study (1990–1993)
until the date of diagnosis of atrial ﬁbrillation, the date of death, loss to follow up, or
end of the study period (January 1st, 2008).
2.7. Statistical analyses
Because of the large difference in prevalence of atrial ﬁbrillation between men and
women, all analyses were stratiﬁed by sex. Participants were categorized as those having
unrecognized MI on baseline ECG, those with clinically recognized MI at baseline, and as
those without a history of MI. Baseline characteristics of all participants were compared
according to these categories. We then assessed the association of recognized and
unrecognized MI with atrial ﬁbrillation, using Cox proportional hazards regression analy-
ses. First, we adjusted only for age. Age-adjusted hazard curves are presented comparing
the cumulative incidence of atrial ﬁbrillation between theMI categories. Second, we addi-
tionally adjusted for the following cardiovascular risk factors at baseline: systolic and di-
astolic blood pressure, use of blood pressure lowering medication, BMI, total and HDL
cholesterol, smoking status, diabetes mellitus, COPD, and heart failure. Finally, we adjust-
ed for incident heart failure during follow-up (time-dependent). Approximately 5% of the
participants had missing values for one or more covariables. These missing values were
handled using the expectation maximization algorithm. All measures of association are
presented with 95% CIs. Data were analysed using the SPSS PASW statistical package, ver-
sion 17.0 (IBM corporation).
3. Results
3.1. Baseline characteristics
Baseline characteristics of the study population are described in
Table 1. The population included 2505 men of whom 142 were classi-
ﬁed with an unrecognized MI and 270 with a recognized MI. Of the
3670 women, 193 were classiﬁed with an unrecognized MI and 112
with a recognizedMI. Compared to thosewithout a history ofMI, partic-
ipants with an unrecognized MI were older, had higher systolic and di-
astolic blood pressure, were more likely to smoke and to have heart
failure independent of age. Men with unrecognized MI were also
more likely to have diabetes thanmenwithout MI. Compared to partic-
ipants with a recognized MI, participants with an unrecognized MI had
a higher systolic blood pressure, were less likely to use blood-pressure
lowering medication and were less likely to have been diagnosed with
heart failure. Additionally, men with unrecognizedMI were more likely
to smoke than those with a recognized MI. During a mean follow-up of
11.7 years (SD5.0), 727 participants, ofwhom329men, developed atri-
al ﬁbrillation, and 2,301 died. During follow-up, 638 participants devel-
oped heart failure.
3.2. Unrecognized MI and risk of atrial ﬁbrillation
Fig. 1 displays the age-adjusted hazard curves for developing atrial
ﬁbrillation for men and women separately, based on the presence of
recognized and unrecognized MI. Compared to men without MI,
men with unrecognized MI had a higher risk of atrial ﬁbrillation
(age-adjusted HR of atrial ﬁbrillation: 2.36 (95%CI: 1.62 to 3.43)
(Table 2). The age-adjusted HR of atrial ﬁbrillation in men with recog-
nized MI was 1.70 (95%CI: 1.26 to 2.31). Additional adjustment for
the other covariables slightly attenuated the estimate to 2.21
(95%CI: 1.51 to 3.23) for unrecognized MI and remained unchanged
for recognized MI. Finally, adjustment for heart failure during
follow-up lowered the associations to 2.03 (95%CI: 1.38 to 2.97) for
unrecognized MI and 1.48 (95%CI: 1.07 to 2.05) for recognized MI.
Table 1
Baseline characteristics of the study population.
Men Women
Characteristics No MI Recognized MI Unrecognized MI No MI Recognized MI Unrecognized MI
N 2093 270 142 3365 112 193
Age (years) 67.2 (7.9) 68.8 (9.0)a 69.7 (8.6)a 68.8 (9.0) 74.6 (8.6)a 74.0 (9.3)a
Systolic blood pressure (mmHg) 139 (22) 135 (20)b 144 (21)b, c 139 (23) 138 (26) 147 (20)b, c
Diastolic blood pressure (mmHg) 75 (11) 72 (10)b 76 (13)c 73 (11) 70 (14)b 75 (11)b,c
Blood pressure lowering drugs 445 (21.3) 185 (68.5)b 36 (25.4)c 1021 (30.3) 91 (81.3)b 69 (35.8)c
Total cholesterol (mmol/L) 6.3 (1.2) 6.5 (1.2) 6.4 (1.2) 6.9 (1.2) 7.0 (1.3) 6.9 (1.3)
HDL cholesterol (mmol/L) 1.2 (0.3) 1.1 (0.3) 1.2 (0.3) 1.5 (0.4) 1.3 (0.4) 1.4 (0.3)
BMI (kg/m2) 25.6 (2.9) 26.1 (3.1)b 25.8 (3.6) 26.7 (3.9) 27.3 (3.9) 27.8 (5.0)b
Smoking
– Never 179 (8.6) 14 (5.2)b 11 (7.7) 1794 (53.3) 57 (50.9)b 106 (54.9)
– Current 626 (29.9) 58 (21.5)b 58 (40.8)b,c 622 (18.5) 19 (17.0) 38 (19.7)b
– Former 1288 (61.5) 198 (73.3)b 73 (51.4)b,c 949 (28.2) 36 (32.1)b 49 (25.4)
Diabetes 183 (8.7) 42 (15.6)b 25 (17.6)b 322 (9.6) 20 (17.9) 27 (14.0)
COPD 106 (5.1) 13 (4.8) 5 (3.5) 88 (2.6) 2 (1.8) 4 (2.1)
Heart failure 14 (0.7) 29 (10.7)b 8 (5.6)b, c 55 (1.6) 28 (25.0)b 20 (10.4)b, c
Q-wave MI on ECG 0 (–) 145 (53.7) 142 (100.0) 0 (–) 51 (45.5) 193 (100.0)
All values are means (standard deviations) or absolute numbers (%).
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; HDL, high-density lipoprotein; MI, myocardial infarction; N. number
at risk.
a p-valueb0.05, compared with no MI.
b p-valueb0.05, compared with no MI, adjusted for age.
c p-valueb0.05, compared with recognized MI, adjusted for age.
Fig. 1. Age-adjusted hazard curves for the risk of atrial ﬁbrillation for men and women,
separately.
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tion. Adjusted for age, the HR was 0.99 (95%CI: 0.64 to 1.54), and ad-
ditional adjustment for the other risk factors only slightly changed
this estimate (HR: 0.92, 95%CI: 0.59 to 1.44). Recognized MI was sig-
niﬁcantly associated with atrial ﬁbrillation in women, when adjusted
for age (HR: 1.64, 95%CI: 1.02 to 2.65). However, after adjustment for
other risk factors this association was no longer statistically signiﬁ-
cant (HR: 1.36, 95%CI: 0.82 to 2.26).4. Discussion
4.1. Main ﬁndings
Our results indicate that unrecognized MI in men is associated
with a more than two-fold increased risk of developing atrial ﬁbrilla-
tion, compared to men without a history of MI. This association was
independent of cardiovascular risk factor. In women, unrecognized
MI was not associated with an increased risk of atrial ﬁbrillation.Table 2
Hazard rates on the association of unrecognized MI with atrial ﬁbrillation, stratiﬁed on
sex.
Model 1a Model 2b
N n (%) HR (CI) HR (CI)
Men
No MI 2093 248 (11.8) 1.0 (Ref.) 1.0 (Ref.)
Recognized MI 270 50 (18.5) 1.70 (1.26–2.31) 1.66 (1.21–2.29)
Unrecognized MI 142 31 (21.8) 2.36 (1.62–3.43) 2.21 (1.51–3.23)
Women
No MI 3365 359 (10.7) 1.0 (Ref.) 1.0 (Ref.)
Recognized MI 112 18 (16.1) 1.64 (1.02–2.65) 1.36 (0.82–2.26)
Unrecognized MI 193 21 (10.9) 0.99 (0.64–1.54) 0.92 (0.59–1.44)
Abbreviations: HR, Hazard rate ratio; MI, myocardial infarction; N, number at risk; n,
number of atrial ﬁbrillation events (% of N).
a Adjusted for age.
b Additionally adjusted for systolic and diastolic blood pressure, use of blood pres-
sure lowering drugs, BMI, total cholesterol, HDL cholesterol, smoking status, diabetes
mellitus, chronic obstructive pulmonary disease and/or heart failure at baseline.
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Unrecognized MI has previously been associated with an in-
creased risk of cardiovascular and total mortality comparable to rec-
ognized MI [13,15–17]. Furthermore, unrecognized MI is reported to
be associated with increased risks of morbidities, such as recurrent
coronary heart disease [30,31], stroke [31], and heart failure [31].
These results were later replicated within the Rotterdam Study for
stroke, [32] heart failure [33] and also dementia [34]. Like our current
results, these studies showed that unrecognized MI was a strong risk
factor for disease in men, but not in women.
Benjamin et al. previously showed that the association of recog-
nized MI with atrial ﬁbrillation was different for men and women
[4]. They found that clinically recognized MI was signiﬁcantly associ-
ated with atrial ﬁbrillation in men, independent of cardiovascular risk
factors. In women however, recognized MI was associated with atrial
ﬁbrillation after adjustment for age, but this association was no lon-
ger statistically signiﬁcant after adjustment for other cardiovascular
risk factors. Our results show a similar difference in prognosis be-
tween men and women for both recognized and unrecognized MI.4.3. Possible mechanisms
Several mechanisms may explain the association of MI with atrial
ﬁbrillation. Possibly atrial dysfunction or atrial stretching in response
to infarction plays a role. This can lead to increased atrial pressures
and a restrictive ﬁlling pattern, which has previously been related to
development of atrial ﬁbrillation [35]. Moreover, in reaction to atrial
stretching catecholamines are produced, which have previously
been associated with atrial ﬁbrillation [36]. Also it has been suggested
that atrial ﬁbrillation follows secondary to left ventricular dysfunction
and hemodynamic disturbances after MI [37,38]. Finally, atrial ische-
mia might create both atrial ﬁbrillation triggers as well as a substrate
for atrial ﬁbrillation maintenance [39]. It is unclear why the associa-
tion of MI with atrial ﬁbrillation is different between men and
women. In our study, recognized MI was associated with AF in men
and women after adjustment for age. In women this association did
not remain statistically signiﬁcant after adjustment for cardiovascular
risk factors. It might be possible this can be explained by a lack of
power. However it has also been suggested that in response to
acute coronary ischemia women are relatively protected from apo-
ptosis and experience less adverse cardiac remodeling than men
[[]]. It remains to be elucidated to what extent this contributes to
the development of atrial ﬁbrillation.
While for recognizedMI the risk estimatewas lower in women than
in men, the most obvious difference between men and women was
seen for unrecognized MI. It has been suggested that the pathophysiol-
ogy of unrecognized MI is similar to those that go clinically recognized
[18]. This suggests that the most likely explanation for the absence of
the association of unrecognized MI with atrial ﬁbrillation in women is
misclassiﬁcation of this condition. Murabito et al. suggested that ECG
abnormalities not caused by coronary artery disease but resulting
frommisplacement of ECG electrodes due to difﬁcultieswith lead place-
ment owing to breast tissue, can be mistaken for MI [41]. Nevertheless,
the reason behind the currently identiﬁed gender differences remains
unexplained and deserve further evaluation.
Finally, our results suggest that the risk of atrial ﬁbrillation is
somewhat higher for those with unrecognized MI than for those
with recognized MI. We also found that those with an unrecognized
MI had higher systolic and diastolic blood pressure, were less likely
to use antihypertensive drugs, and were more likely to smoke, com-
pared to those with recognized MI. It is possible that lifestyle changes
and treatment following the diagnosis of MI, lower the risk of atrial ﬁ-
brillation and thereby explain why recognized MI is associated with a
lower risk of atrial ﬁbrillation than unrecognized MI.4.4. Strengths and limitations
Strengths of this study are the population-based design, with a
long-term follow-up of 11.7 years. We were able to use data from a
large population that included 6175 participants of whom 335 had
ECG characteristics matching an unrecognized MI at baseline and
692 who developed atrial ﬁbrillation during follow-up. Also, at base-
line we did not inform participants or their treating physicians about
the ﬁnding of an unrecognizedMI on their ECG. The decision reﬂected
the perception at that time that an unrecognized MI was less severe
than a recognized MI, and was motivated by a lack of evidence that
treatment could effectively reduce the risk of subsequent cardiovas-
cular disease [32]. Our results therefore adequately assess the natural
history of unrecognized MI with atrial ﬁbrillation in the general pop-
ulation. Since the fourth research visit in 2002 we started to report
ﬁndings of unrecognized MI to the participants and treating doctors.
By combiningmultiple sources of data on the occurrence of atrial ﬁ-
brillation we limited the chance of misclassiﬁcation. It is possible that
the classiﬁcation of unrecognized MI includes some misclassiﬁcation,
for instance in the case of non-Q-wave MIs or Q-waves that have
disappeared over time. Finally, because we were unaware of the exact
date of the occurrence of the unrecognized MI, we used the date of
the ECGas the date of unrecognizedMI diagnosis. This restricts our ﬁnd-
ings to the long-term risk of atrial ﬁbrillation. Finally we were not able
to adjust our analyses for valvular disease or thyroid function which
are known risk factors of atrial ﬁbrillation.
5. Conclusion
Unrecognized MI as identiﬁed by ECG is associated with a more
than twice increased risk of atrial ﬁbrillation in men, compared to
those without an MI. Atrial ﬁbrillation is an important health prob-
lem. Subjects with unrecognized MI are not treated for the disease,
while detection of the MI followed by lifestyle changes and appropri-
ate treatment may lower the risk of atrial ﬁbrillation.
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